Cybin Inc. Their mission is to create safe and effective therapeutics to address a multitude of mental health issues. With a network of world-class partners and internationally-recognized scientists, Cybin is at the forefront of developing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens.

Working closely with renowned pioneers in the field, Cybin is focused on engineering psychedelic-based therapies to meet the unmet needs of patients. Through their cutting-edge research, they aim to transform the mental health treatment landscape. Their strategy involves combining novel psychedelic molecules with controllable drug delivery systems through their proprietary deuterated process.

This approach allows for the development of next-generation psychedelic drug candidates that are patent-protected and commercially scalable. Cybin currently has active drug programs targeting Major Depressive Disorder, Alcohol Use Disorder, Generalized Anxiety Disorder, and Neuroinflammation. Backed by an experienced team with deep-rooted expertise in psychiatry and psychedelics drug development, Cybin is committed to making a meaningful impact on mental healthcare